Evidence map›Paper›PMID 40593578›Full record

ArticleNature communications2025

Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny.

Theodore S Nowicki, Nataly Naser Al Deen, Cole W Peters, Begoña Comin-Anduix, Egmidio Medina, Cristina Puig-Saus, Ignacio Baselga Carretero, Paula Kaplan-Lefko, Mignonette H Macabali, Ivan Perez Garcilazo and 23 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03240861 (Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03240861 phase1terminatednot on this map

Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies

TypeinterventionalSponsorJonsson Comprehensive Cancer CenterRan2017 to 2023Enrolled5ConditionsHLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive, Unresectable Malignant NeoplasmArms18F-FHBG, Aldesleukin, Busulfan, Cellular Therapy, Computed Tomography
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Theodore S NowickiDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA. tnowicki@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-3815-6137
Nataly Naser Al DeenDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Cole W PetersDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-7052-1432
Begoña Comin-AnduixJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
Egmidio MedinaDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-3284-5329
Cristina Puig-SausDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-3014-3649
Ignacio Baselga CarreteroDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Paula Kaplan-LefkoDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Mignonette H MacabaliDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0009-0007-9861-7234
Ivan Perez GarcilazoDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Daniel ChenDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-6660-6257
Jia PangDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Beata Berent-MaozDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Salem HaileJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
Jonathan RodriguezDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-3201-3407
Moe KawakamiDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0009-0008-6981-8114
Conner K KiddDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-0152-2877
Ameya ChamphekarDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Giuseppe CarlucciDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Agustin Vega-CrespoDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Bartosz ChmielowskiJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-2374-3320
Arun SinghDivision of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Noah FedermanDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA.
Gary M SchillerJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-7508-3467
Sarah J LarsonJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
Martin Allen-AuerbachDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Alexandra M KlomhausDepartment of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-7676-3595
Jerome ZackDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, USA.
David BaltimoreDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.ORCID http://orcid.org/0000-0001-8723-8190
Lili YangDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, USA.
Donald B KohnDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-1840-6087
Owen N WitteDepartment of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA, USA.
Antoni RibasJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-3669-8458

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
Project 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8M
Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
Functional epigenomics of transgenic cellular immunotherapies for cancerK08CA241088 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NOWICKI, THEODORE SCOTT · 2021 to 2025
$909k
California Institute for Regenerative Medicine (CIRM) CLIN2-11380California Institute for Regenerative Medicine (CIRM) INFR4 Alpha Clinic Network Expansion AwardNCATS NIH HHS UL1 TR001881NCI NIH HHS K08 CA241088NCI NIH HHS P01 CA244118NCI NIH HHS P30 CA016042NCI NIH HHS R35 CA197633NIAID NIH HHS P30 AI028697U.S. Department of Health & Human Services | National Institutes of Health (NIH) UL1TR001881
6 · The paper itself

Abstract

Adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical responses in a variety of malignancies. However, these responses are frequently short-lived, and patients typically relapse within several months. This phenomenon is largely due to poor persistence of the transgenic T cells, as well as a progressive loss of their functionality and terminal differentiation in vivo. This underscores the need for cell therapy approaches able to sustain the initial antitumor efficacy and lead to long-term antitumor efficacy. Herein, we report the use of tandem cell therapies involving autologous T cells and hematopoietic stem cells engineered to express the NY-ESO-1 TCR for the treatment of solid tumors in a first-in-human phase I clinical trial (NCT03240861). This therapy is shown to be safe, feasible, and leads to initial tumor regression activity. T cell progeny from the HSC progenitors is shown to provide circulating transgenic NY-ESO-1 TCR-T cells, which display tumor-antigen-specific antitumor functionality, without any evidence of anergy or exhaustion. These results demonstrate the utility of transgenic HSCs to generate a self-renewing source of tumor-specific cellular immunotherapy in human participants. Clinicaltrials.gov: NCT NCT03240861.

Indexed as

Hematopoietic Stem CellsHematopoietic Stem Cell TransplantationImmunotherapy, AdoptiveNeoplasmsT-LymphocytesAntigens, NeoplasmFemaleHumansMaleMembrane ProteinsReceptors, Antigen, T-CellAntigens, NeoplasmCTAG1B protein, humanMembrane ProteinsReceptors, Antigen, T-Cell

Identifiers

PMID40593578
PMCPMC12219382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.